Publications

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice

Developmental deletion of amyloid precursor protein precludes transcriptional and proteomic responses to brain injury

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice

Developmental deletion of amyloid precursor protein precludes transcriptional and proteomic responses to brain injury

Swedish Alzheimer’s disease variant perturbs activity of retrograde molecular motors and causes widespread derangement of axonal transport pathways

Amyloid precursor protein induces reactive astrogliosis

A systematic assessment of robustness in CNS safety pharmacology

Immunotherapy Targeting the C-Terminal Domain of TDP-43 Decreases Neuropathology and Confers Neuroprotection in Mouse Models of ALS/FTD

The GBA1 D409V Mutation Exacerbates Synuclein Pathology to Differing Extents in two Alpha-Synuclein Models

Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake

Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax